Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma

Cancers

Michael C. Stauder¹ 

[1] Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA; E-Mail

关键词: stereotactic radiotherapy;    radiotherapy;    pancreatic neoplasms;   

DOI  :  10.3390/cancers2031565

来源: mdpi

【 摘 要 】

Survival in patients with unresectable pancreatic carcinoma is poor. Studies by Mayo Clinic and the Gastrointestinal Tumor Study Group (GITSG) have established combined modality treatment with chemotherapy and radiation as the standard of care. Use of gemcitabine-based chemotherapy alone has also been shown to provide a benefit, but 5‑year overall survival still remains less than 5%. Conventional radiotherapy is traditionally delivered over a six week period and high toxicity is seen with the concomitant use of chemotherapy. In contrast, SBRT can be delivered in 3–5 days and, when used as a component of combined modality therapy with gemcitabine, disruption to the timely delivery of chemotherapy is minimal. Early single-institution reports of SBRT for unresectable pancreatic carcinoma demonstrate excellent local control with acceptable toxicity. Use of SBRT in unresectable pancreatic carcinoma warrants further investigation in order to improve the survival of patients with historically poor outcomes.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.